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Abstract
Background: Human papillomavirus (HPV) is one of the most common sexually-transmitted pathogens. A number of
studies in the literature have estimated the burden of HPV-related diseases by collecting data at primary care level,
while a comprehensive assessment of the global burden of HPV-related diseases on hospital resources is still lacking.
Methods: This was a retrospective cohort study based on hospital discharge data collected from 2000 to 2010 in the
Veneto Region (north-east Italy). All hospitalizations for diseases potentially associated with HPV were identified by
searching the hospital discharge records, then the proportion of these hospitalizations relating to diseases attributable
to the HPV infection was calculated.
Results: Overall, the annual hospitalization rate for HPV-related diseases was 21.3 per 100,000 individuals in the
general population, 15.8 per 100,000 males, and 27.6 per 100,000 females. Hospitalizations were due mainly to
genital warts, and peak among 15- to 44-year-olds in both genders. Taking both sexes together, the hospitalizations
attributable to HPV dropped from 24.5/100,000 in 2000 to 17.5/100,000 in 2011, showing a significant decline during
this period, with an average annual percent change (AAPC) of −1.9% (CI 95%: -2.8, -0.9;). On the other hand, the
hospitalization rate for genital warts tended to increase significantly (AAPC 3.0% [CI 95%: 1.4;4.7]), whilst there was a
significantly declining trend in the hospitalization rate for anal cancer (AAPC - 5.0% [CI 95%: -7.7;-2.2]), genital cancer
(AAPC −6.2% [CI 95%: -7.8;-4.6]) and oropharyngeal cancer (AAPC −4.3% [CI 95%: -4.8;-3,8]).
Conclusion: Data derived from the hospital records indicate that HPV-related diseases are an important public
health issue.
Background
Human papillomavirus (HPV) is the most common
sexually-transmitted pathogen [1]. In the USA, more than
one in two sexually-active individuals become infected
with one or more types of HPV at some point in their
lives. Recent research indicates that, at some point in
time, 42.5% of women have had genital HPV infections,
whereas less than 7% of adults have had oral HPV infec-
tions [2,3]. The estimated overall epidemiological burden
of HPV-related cancers and non-malignant diseases is
very high in Europe too [4].
Most infections are asymptomatic and transient, but
certain HPV types are oncogenic. Numerous studies have
identified many biochemical features that contribute to
HPV-induced carcinogenesis, such as the ability of the
viral proteins E6 and E7 to bind cellular factors, and
biological properties like the capacity of HPV proteins
to induce cell immortalization [5].
Genital infection with oncogenic or high-risk types of
HPV is a causal factor in cervical cancer; the HPV types
mainly involved are 16 and 18, which are responsible for
approximately 70% of cases of this cancer. HPV also has
a well-known role in premalignant lesions of the cervix,
vulva and vagina, and the International Agency for Re-
search on Cancer (IARC) has recently supported (with
“sufficient” or “limited” evidence) the carcinogenicity of
HPV in the penis, anus, oral cavity, oropharynx, tonsils
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and larynx [6]. A recent review found that HPV was
considered responsible for about 88% of anal cancers in
both sexes, 70% of vaginal cancers, 43% of vulvar can-
cers and 50% of penile cancers [7]. Many authors have
highlighted the role of HPV in cancers involving the
oropharynx and oral cavity too [8]. In 2005 Kreimer et al.
conducted a systematic meta-analysis on the available
literature on the topic and ascertained the worldwide
prevalence of HPV in neck squamous cell carcinoma,
which was estimated at 26% [9].
HPV is responsible for several benign diseases as well,
e.g. genital warts, that have a significant economic and
psychological impact [10,11]. Genital warts are the most
commonly diagnosed disease among males referred to cen-
ters for the treatment of sexually-transmitted diseases [8].
A number of studies in the literature have estimated
the burden of HPV-related diseases by collecting data
at primary care level, while only one European study
(conducted in Spain) used the hospitalization records
to ascertain the burden of HPV related to anal and penile
neoplasms [12]. No comprehensive assessments have been
conducted on the overall burden of HPV-related diseases
on hospital resources. Though by no means the only
burden of HPV-related diseases, the related hospitalization
costs are certainly the most important in economic terms.
The aim of the present study was to estimate the
burden of hospitalization for HPV-related diseases, strati-
fied by sex, in a population of almost five million citizens.
Methods
To estimate the annual HPV-associated hospitalization
rates, we analyzed the data in the hospital records from
2000 to 2011 in the Veneto Region (north-east Italy)
concerning all discharges from all public and accredited
private hospitals, including day hospital services. HPV-
associated hospitalization were identified by selecting
all the hospital discharge records containing one of the
following codes in the International Classification of
Diseases, Ninth Revision, Clinical Modification (ICD-9-CM):
genital warts; 078.11 “Condyloma acuminatum”; anal cancer;
154.2-154.8 “Malignant neoplasm of anus”; oropharyngeal
cancer; 146.0-146.9 “Malignant neoplasm of oropharynx”;
171.0 “Malignant neoplasm of head, face, and neck”;
genital cancer; 187.1-187.9 “Malignant neoplasm of penis”;
180.0-180.9 “Malignant neoplasm of cervix uteri”.
Only admissions for which HPV-related diseases were
indicated as the main diagnosis at the time of discharge,
were drawn from the database. The proportion of hospi-
talizations for diseases potentially associated with HPV
infection was calculated on the assumption that all dis-
charges for cervical cancer and genital warts were HPV-
related, while this was true of 50% and 88%, respectively,
of cancers of the male genitalia (penis) and anus, and
applied to 26% of oropharyngeal cancers [7–9]. The
HPV-related hospitalization rate was calculated from the
number of discharges as a proportion of the Veneto’s resi-
dent population in a given year.
Significant trends over the years considered were assessed
as average annual percent changes (AAPC), a summary
measure of the trend over a given fixed interval. It is com-
puted as a weighted average of the annual percent change
(APC) emerging from the join-point model, using weights
equating to the length of the APC interval. If an AAPC lies
entirely within a single join-point segment, the AAPC is
the same as the APC for that segment [13].
Data were obtained from the Regional Statistics Office
and analyzed using EPI-Info 2000 software (Center for
Disease Control and Prevention of Atlanta, GA, USA) and
the Joinpoint Regression Program, rel. 4.0.4. May 2013
(Statistical Research and Applications Branch, National
Cancer Institute, USA).
The study was conducted on data routinely collected
by the health services linked to anonymized records that
make it impossible to identify the individuals concerned.
The data analysis was performed on the anonymized
aggregated data. Data in the Local Health Authority regis-
tries are recorded with the patient’s consent and can be
used as aggregated data for scientific studies without
further authorization [14]. This study complies with the
Declaration of Helsinki and with Italian privacy law
(Decree n. 196/2003 on the protection of personal data).
Results
We identified 16,659 hospitalizations for diseases poten-
tially associated with HPV between January 1, 2000 and
December 31, 2011. The proportion of these hospital ad-
missions attributable to HPV was calculated to be 12,410
(74.5% of the total), comprising 4,384 males (35.3%) and
8,026 females (64.7%). Genital warts were the most com-
mon HPV-related condition prompting admission to
hospital (44.9%).
Genital warts were usually associated with age under
45 years (4,613; 82.8%), while the HPV-related cancers
were more common in patients aged ≥ 45 years (5,728;
83.7%). Table 1 shows the HPV-related admissions by
sex and age group.
Overall, the average hospitalization rate for HPV-related
diseases in the years 2000–2011 was 21.8 per 100,000
(15.8 per 100,000 males, and 27.6 per 100,000 females).
Table 2 shows the average hospitalization rate for HPV-
related diseases in 2000–2011 per 100,000 population in
the Veneto Region by type of disease and gender.
Considering both sexes together, the hospitalization rate
attributable to HPV dropped from 24.5/100,000 in 2000
to 17.5/100,000 in 2011; this decline was statistically sig-
nificant, with an AAPC of −1.9% (CI 95%: -2.8, -0.9;)
from 2000 to 2011. On the other hand, the trend of the
hospitalization rate for genital warts increased significantly
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(AAPC 3.0% [CI 95%: 1.4;4.7]), whilst there was a signifi-
cantly declining trend in the hospitalization rate for anal
cancer (AAPC - 5.0% [CI 95%: -7.7;-2.2]), genital cancer
(AAPC −6.2% [CI 95%: -7.8;-4.6]), and oropharyngeal can-
cer (AAPC −4,3% [CI 95%: -4.8;-3.8]).
Over the whole study period, the HPV-attributable
hospitalization rate for males remained stable, going from
16.1/100,000 in 2000 to 14.6/100,000 in 2011 (AAPC 0.2%
[CI 95%: -0,8;1,2]), while for females it decreased from
32.5/100,000 in 2000 to 20.2/100,000 in 2011 (AAPC −2.9%
[CI 95%: -4.2; -1.6]).
Looking at the admissions for HPV-related cancer in
males, the hospitalization rate decreased significantly
for anal cancer (AAPC −4.7% [CI 95%: -7.8; -1.6]) and
oropharyngeal cancers (AAPC −5.2% [CI 95%: -6.1; -4.3]),
while for genital (penis) cancer it remained stable
(AAPC −0.5% [CI 95%: -3.5; 2.5]) (Figure 1). As for the
admissions for HPV-related cancer in females, there
was a significant drop in the figures for genital (cervix)
cancer (AAPC −6.9% [CI 95%: -8.5; -5.3]) and anal can-
cer (AAPC −5.2% [CI 95%: -8.4; -1.9]). For oropharyn-
geal cancer, in female, the hospitalization rates did not
change significantly over the study period (AAPC −0.7%
[CI 95%: -3.1; 1.7]) (Figure 2).
There was a statistically significant increase over the
years in the hospitalization rate for genital warts in males
(AAPC 5.7% [CI 95%: 3.4;8,0]), but not in females (AAPC
1.6% [CI 95%: -0.4; 3.6]) (Figure 3). For these non-
malignant conditions, there was a female predominance
in all age groups, with a female-to-male ratio of 1.8:1.
Figure 4 shows the hospitalization rates for HPV-
related non-malignant diseases by age group and gender.
The highest hospitalization rate was for genital warts in
15- to 44 year-olds of both genders. Hospitalization for
HPV-related cancer increased with age and the female-
to-male ratios were 7.9:1, 1:1, and 1:3.9 for genital, anal
and oropharyngeal cancers, respectively.
Discussion and conclusions
The present study examined the trends in the hospi-
talization rates for different types of HPV-related disease
in a cohort of 5 million citizens and the results show that
the burden of HPV-related diseases on hospital resources
is an important public health issue.
It is not easy to estimate the morbidity of HPV-related
diseases in the general population, partly because the
currently-available epidemiological picture is hazy due
to differences in study designs and population profiles,
access to health care and registration methods (espe-
cially for benign diseases). Hospital discharge data can,
however, be useful for assessing the cases severe enough
to warrant hospitalization [15].
Using discharge diagnoses to identify cases of HPV-
related diseases is more useful for cancer than for benign
diseases. Patients are only hospitalized for genital warts
Table 1 Number of HPV-related hospitalizations in the Veneto Region (2000–2011)
Total Genital warts Genital cancer Oropharyngeal cancer Anal cancer
n (%) n (%) n (%) n (%)
Total 12,410 5,570 (44.9) 3,905 (31.5) 1,258 (10.1) 1,677 (13.5)
Gender
males 4,384 2,097 (47.8) 438 (10.0) 1,000 (22.8) 849 (19.4)
females 8,026 3,473 (43.3) 3,467 (43.2) 258 (3.2) 828 (10.3)
Age group
<14 44 30 (68.2) 2 (4.5) 10 (22.7) 2 (4.5)
15-24 1,230 1,211 (98.5) 12 (0.9) 5 (0.4) 2 (0.2)
25-44 4,451 3,372 (75.8) 951 (21.4) 51 (1.1) 77 (1.7)
45-64 3,657 811 (22.2) 1,621 (44.3) 666 (18.2) 559 (15.3)
65-74 1,544 112 (7.3) 643 (41.6) 339 (22.0) 450 (29.1)
75-84 1,154 31 (2.7) 533 (46.2) 154 (13.3) 436 (37.8)
85+ 331 3 (0.9) 144 (43.4) 33 (10.0) 151 (45.7)
Table 2 Average hospitalization rate in 2000–2011 for
HPV-related diseases per 100,000 population in the
Veneto Region, by disease and gender
Males Females Total
Genital warts 7.5 11.9 9.8
Genital cancer 1.6 11.9 6.9
Anal cancer 3.1 2.8 2.9
Oropharyngeal cancer 3.6 0.9 2.2
Total 15.8 27.6 21.8
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in the more complex cases, and particularly for those
requiring surgical removal [16].
The overall hospitalization rate identified was 21.8/
100,000 population during the calendar years 2000–2011,
and it was 1.8 times higher for females than for males.
This might suggest a gender-related difference in the
natural history of HPV, with lower infection and higher
disease rates in women, and vice versa in men [17,18].
The age groups considered in our sample revealed age-
related differences in the hospitalization rates for the
diseases examined: more older people had cancer and
more younger people had condylomatosis. This picture
may be due to the age groups’ different times of exposure
to HPV, and to different latency periods of the various
diseases [1]. Another significant aspect concerns the
hospitalization rate for genital warts, which accounted
for almost one in five of all HPV-related hospital stays.
For this disease, the hospitalization rate peaked for men
slightly later in life than for women (at 25–44 years of
age in the former and 15–24 in the latter). Our figures
are similar to those reported in North American and
Australian studies [18], whereas the peak age was the
same for the two genders in the United Kingdom and
Nordic countries [19,20].
Our data show that a drop in the hospitalization rates
for women from 2000 to 2011. This concerns the hos-
pitalization for cancer, and cancer of the uterine cervix



































Genital (penis) [AAPC:-0.5 (-3.5;2.5)]
Anal [AAPC:-4.7* (-7.8;-1.6)]
Oropharyngeal [AAPC:-5.2* (-6.1;-4.3)]
Figure 1 Hospitalization rate (× 100,000 population) for HPV-related cancer in males in the Veneto Region (2000–2011), by type
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Oropharyngeal [AAPC:-0.7 (-3.1;1.7)]
Figure 2 Hospitalization rate (× 100,000 population) for HPV-related cancer in females in the Veneto Region (2000–2011), by type
of cancer. * p<0.05.
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screening programs for detecting and treating this dis-
ease in our region. In accordance with Italian national
guidelines, cervical cancer screening programs have been
implemented in the Veneto Region since 1997. They are
based largely on European guidelines and women from
25 to 64 years of age are personally invited for a Pap test
every three years [21].
There was also a smaller drop in the hospitalization
rate for anal cancer, that was statistically significant in
males. A possible explanation for this could lie in changes
in the management of chemotherapy and radiotherapy
for cancer: since 2007 they have been administered not
in hospital but at ambulatory outpatient services [22].
The overall trend of our HPV-related hospitalizations
nonetheless revealed an increase among males during the
study period. The hospitalization rates rose for genital
warts in males during the period considered (pointing
to the need for prevention programs), but not in females.
A higher prevalence among males of severe HPV-related
warts warranting hospitalization could be expected to
induce a corresponding increase in women too, given
the transmissible nature of HPV [23], but this was not
the case - probably because the early diagnosis of warts
on cervical cancer screening prevented them from
growing enough to need hospitalization.
This study shows that hospitalization for genital warts
has a considerable impact on the health services in the
Veneto Region. Vaccination strategies can be used for the
primary prevention of HPV infection, and could reduce
the burden of HPV-related disease. Two vaccines against
HPV have been developed and are currently used in
population vaccination programs in many countries.
Both have proved highly effective in preventing HPV 16
and 18, which are jointly responsible for approximately
70% of cervical cancers [24]. A quadrivalent vaccine
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Figure 4 HPV-related hospitalization rates (× 100,000 population) in the Veneto Region by gender, type of disease, and age
group (2000–2011).
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also protects against the HPV types responsible for 90%
of genital warts (types 6 and 11) [25]. The economic
burden of HPV-related conditions on hospital resources
should be taken into account when assessing the potential
benefits of HPV vaccines against HPV 6 and 11, since it is
expected that these vaccines will ultimately reduce the
incidence of HPV-related diseases.
Presently there has been ongoing debate over the intro-
duction of HPV vaccination. Before introducing the vac-
cination in males should be considered the vaccination
coverage rate in females, the burden of HPV-related dis-
eases and whether it is programmatically feasible and
economically sustainable.
In Italy, since 2007, free anti-HPV vaccination has been
offered to all girls in their 12th year of life. Two different
vaccines have been available in Italy for the past three
years: a bivalent vaccine directed against HPV types 16
and 18 (involved in cancer of the uterine cervix and
other cancers) and a quadrivalent vaccine against HPV
16 and 18, and 6 and 11 (the latter are responsible for
the onset of external genital lesions, i.e. condylomas and
genital warts, which can affect both genders) [7,8]. A
recently-published Italian progress report on the vaccin-
ation programs identified a mean coverage of 70.6%,
69.7% and 69.3%, respectively, in the 1997, 1998 and
1999 cohorts for the first dose, while the full vaccination
cycle was completed in 66.0%, 64.0% and 58.6% of cases,
respectively. In the Veneto Region, the coverage was
76.8%, 73.6% and 61.3%, respectively, for the female
cohorts in 1997, 1998 and 1999 [26]. As HPV is sexually
transmitted, males play an important part in the pathology
of HPV, not only as transmission agents, but also as
targets of HPV infection, so the universal vaccination
of adolescents would limit its transmission and signifi-
cantly reduce the virus’s circulation in the general popula-
tion. It could also have the advantage of reducing the
rate of HPV-related disease among males, which is far
from negligible, as the present study demonstrates. The
high proportions of HPV-positive cancers attributable
to HPV16/18, and of non-malignant diseases attribut-
able to HPV6/11 underscore the potential importance
of preventing the majority of male HPV-related diseases
by means of prophylactic vaccination [27].
Our study has some limitations. Among them, we
should consider the dubious accuracy of the total num-
ber of HPV-related hospital admissions identified due
to coding errors in the hospital records. Another limit
lies in that the responsibility of HPV could not be tested
because no virology data were available. Judging from
our hospitalization records, it would seem important to
conduct prospective epidemiological studies with the
cooperation of specialists in this field, with a view to
obtaining a more precise picture of the epidemiological
situation regarding HPV-related diseases.
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